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Transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel with high 
Ca2+ permeability, which functions as a polymodal nociceptor activated by heat, protons and 
several vanilloids, including capsaicin and anandamide. Although TRPV1 channels are widely 
distributed in the mammalian brain, their pathophysiological roles in the brain remain to be 
elucidated. In this study, we investigated whether TRPV1 is involved in cerebral ischemic injury 
using a middle cerebral artery (MCA) occlusion model in wild-type (WT) and TRPV1-knockout 
(KO) mice. For transient ischemia, the left MCA of C57BL/6 mice was occluded for 60 min and 
reperfused at 1 and 2 days after ischemia. We found that neurological and motor deficits, and 
infarct volumes in TRPV1-KO mice were lower than those of WT mice. Consistent with these 
results, intracerebroventricular injection of a TRPV1 antagonist, capsazepine (20 nmol), 30 min 
before the onset of ischemia attenuated neurological and motor deficits and improved infarct 
size without influencing cerebral blood flow in the occluded MCA territory. The protective 
effect of capsazepine on ischemic brain damage was not observed in TRPV1-KO mice. WT and 
TRPV1-KO mice did not show any differences with respect to the increased number of 
Iba1-positive microglia/macrophages, GFAP-positive astrocytes, and Gr1-positive neutrophils at 
1 and 2 days after cerebral ischemia. Taken together, we conclude that brain TRPV1 channels 
are activated by ischemic stroke and cause neurological and motor deficits and infarction after 





Stroke is the second most common cause of death worldwide [1] and the leading cause of adult 
disability [2]. The burden of stroke is predicted to increase greatly with the anticipated increase 
in the aging population, which will increase further the demand for new therapies [2]. In fact, 
current therapeutic approaches, using antiplatelet and thrombolytic agents, only partially 
ameliorate the clinical outcome of stroke patients since these drugs are not aimed at 
counteracting the mechanisms associated with neuronal cell death, but at preserving or restoring 
cerebral blood flow [3].  
  Transient Receptor Potential Vanilloid 1 (TRPV1), one of the best characterized members of 
the TRP channel family, is a capsaicin receptor (also known as vanilloid receptor VR1) and is 
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activated not only by capsaicin but also by heat (>43°C), acid (pH <6.0), and various lipids, i.e., 
unsaturated N-acyl-dopamines, lipoxygenase products from arachidonic acid, an 
endocannabinoid anandamide, 2-arachidonoyl-glycerol, and omega-3 polyunsaturated fatty 
acids [4]. Although TRPV1 is involved in peripheral nociception, TRPV1 is widely expressed in 
the rodent brain, including the hippocampus, cortex, cerebellum, olfactory bulb, mesencephalon, 
and hindbrain [5, 6], suggesting that TRPV1 has a physiological role in the CNS. In this context, 
stimulation of TRPV1 in the ventral midbrain selectively accelerates glutamatergic inputs to 
midbrain dopaminergic neurons [7]. Moreover, recent research shows that TRPV1 is involved in 
synaptic plasticity in hippocampal interneurons [8], dentate gyrus [9], and nucleus accumbens 
[10]. Despite evidence suggesting that TRPV1 has a physiological role in the CNS, little is 
known about its pathophysiological role in neurological disorders, especially in cerebral 
ischemic injury.  
  Therefore, to investigate the possible involvement of TRPV1 in neuronal damage after 
cerebral ischemia in vivo, we evaluated the effects of TRPV1 deficiency and blockade on 
infarcted brain volume and neurological and motor function using a mouse model of transient 
focal cerebral ischemic stroke. 
 
MATERIALS AND METHODS 
 
Animals 
Male TRPV1-KO and WT mice at 8 weeks of age weighing 20–30 g were used in this study. 
TRPV1-KO mice were originally provided by Dr Julius and were maintained in our laboratory 
at a constant ambient temperature of 22 ± 1°C under a 12-h light/dark cycle, and were fed water 
and chow ad libitum. The experiments were conducted in accordance with the ethical guidelines 
of Kyoto University Animal Experimentation Committee and the Guidelines of the Japanese 
Pharmacological Society. 
 
Transient middle cerebral artery (MCA) occlusion  
Mice were anesthetized with 1% halothane in 30% O2 and 70% N2O using a face mask. After a 
midline skin incision, the left common carotid artery and external artery were isolated and 
ligated. An 8–0 nylon monofilament coated with silicon (180–200 mm in diameter) was 
introduced into the left internal carotid artery through the common carotid artery to occlude the 
origin of the MCA. After 60 min of occlusion, the monofilament was withdrawn to allow 
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reperfusion and the mouse was placed in a thermally controlled incubator (32.0°C) for 2 h 
before being returned to its cage. Rectal temperature was maintained at 37.0 ± 0.5°C with a 
thermostat-controlled heating pad throughout the operation. Regional cerebral blood flow 
(rCBF) in the MCA territory was monitored by Laser Dopplar Flowmetry (Omegaflow; 
Omegawave Inc., Tokyo, Japan). A flexible probe was fixed to the skull (2 mm posterior and 6 
mm lateral to bregma) before MCA occlusion. Only mice showing <20% of baseline rCBF in 




The TRPV1 antagonist capsazepine was injected 1 mm posterior and 1 mm lateral to the bregma 
on the left side. A 23-G needle attached to a Hamilton microsyringe was inserted so that its tip 
was located 3 mm beneath the dural surface. The needle was kept in the same position for 1 min 
before removal. Capsazepine was dissolved in 20% DMSO/80% phosphate-buffered saline 
(PBS) and administered at a dose of 20 nmol/5 μl per mouse. 
 
Neurological deficit score 
Neurological deficiency was evaluated using a 5-point neurological deficit score test. After 
several days of ischemia, mice were tested for behavioral changes and scored as follows: 0, no 
deficit; 1, flexion of contralateral forelimb and torso upon lifting the animal by the tail; 2, 
circling to the ipsilateral side but normal posture at rest; 3, circling to the ipsilateral side; 4, 
rolling to the ipsilateral side; and 5, no spontaneous motor activity. 
 
Rope grip test 
Motor dysfunction was evaluated by using the 5-point rope grip test. After several days of 
ischemia, mice were tested for behavioral changes and scored as follows: 0, escape; 1, grasping 
the tightrope with the four legs and the tail; 2, hanging from the forelimbs and the hindlimbs; 3, 
hanging from the forelimbs; 4, trying to hang from the forelimbs; and 5, fall. The final score 
was the average of five trials. 
 
Measurement of infarct volume 
After neurological deficit score evaluation, mice were sacrificed, the brains were removed, and 
the forebrains were sliced into eight coronal 1-mm sections using a mouse brain matrix. The 
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slices were placed in 2% 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C for 20 min. The 
infarct area of each brain slice was quantified using image analysis software (Image J). The 
infarct volumes were calculated by multiplying each area by the slice thickness. 
 
Immunohistochemistry and Immunofluorescence 
Mice were intraperitoneally injected with 50 mg/kg pentobarbital and perfused transcardially 
with 0.1 M PBS followed by 4% paraformaldehyde in 0.1 M PBS. Brains were stored in 
fixative for 3 h and then transferred into 0.1 M PBS containing 15% sucrose for 24 h. Coronal 
sections with a 20 μm thickness were obtained using a cryomicrotome (Leica, Bensheim, 
Germany). Brain sections were soaked in 0.1% Triton X100 for permeabilization and then 
incubated overnight at 4°C with the following primary antibodies: a rabbit polyclonal anti-Iba1 
antibody (1:500 dilution, Wako); a rabbit polyclonal anti-GFAP antibody (1:1000 dilution, 
DAKO); and a rat monoclonal anti-Gr1 (Ly6G) antibody (1:300 dilution, R&D Systems). For 
immunofluorescence, sections were incubated with secondary antibodies (Alexa Flour 
594-labeled donkey anti-rabbit IgG (1:300 dilution, Molecular Probes) and Alexa Flour 
488-labeled donkey anti-rat IgG (1:300 dilution, Molecular Probes)) for 1.5 h in the dark at 
room temperature. Immunofluorescence was visualized with an Olympus FluoView microscope 
equipped with a laser scanning confocal imaging system. The number of Iba1- and 
GFAP-immunoreactive cells in the peri-ischemic area was counted in five 500 × 500 μm2 fields 
at approximately +0.7 mm from bregma. The number of Gr1-positive cells in the ischemic core 
area was counted in five 500 × 500 µm2 fields at approximately +0.7 mm from bregma. 
 
Data analysis 
Data are presented as the mean ± SEM and were analyzed using GraphPad Prism version 5.0. 
Neurological deficit scores, results of the rope grip test, and infarct volumes were analyzed 
using Student’s t-test. The numbers of Iba1+ or GFAP+ cells were analyzed by two-way analysis 
of variance (ANOVA) followed by the post hoc Bonferroni test. In all cases, differences of p < 





TRPV1 gene deficiency improves neurological outcome and reduces infarct volume 
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To investigate the involvement of TRPV1 in ischemic-reperfusion injury, we examined the effects 
of TRPV1 deficiency on ischemic brain injury using a mouse focal ischemia model. The left MCA 
was occluded for 60 min followed by reperfusion. MCA occlusion in WT and TRPV1-KO mice 
decreased rCBF to <20% of baseline and reperfusion restored rCBF. No differences in rCBF were 
observed between the two mouse genotypes (Fig. 1A). Neurological deficiency levels were similar 
between WT and TRPV1-KO mice at 1 day after ischemia; however, at 2 days after reperfusion, 
TRPV1-KO mice showed less neurological deficiency than WT mice (Fig. 1B). Motor 
dysfunction was less severe in TRPV1-KO mice than in WT mice at 1 and 2 days after reperfusion 
(Fig. 1C). Infarct volume was evaluated by TTC staining after performing the behavioral test. The 
volume in TRPV1-KO mice was significantly lower than that in WT mice at 2 days after ischemia. 
(Fig. 1D and E).  
 
Protective effect of capsazepine on neurological deficit and infarct volume 
Gene inactivation is known to result in some cases in the activation of compensatory or 
redundancy mechanisms that counteract the loss of gene function. Therefore, we investigated the 
effects of the TRPV1 antagonist capsazepine on ischemic brain injury. Thirty minutes after 
intracerebroventricular injection of vehicle or capsazepine (20 nmol), no differences in rCBF were 
observed between either group of mice (Fig. 2A). At 2 days after reperfusion, the degree of 
neurological deficiency and motor dysfunction in capsazepine-treated mice was significantly 
lower than that in vehicle-treated mice (Fig. 2B and C). In addition, the infarct volume was 
significantly smaller in capsazepine-treated mice than in vehicle-treated mice (Fig. 2D and E). 
 
No capsazepine protective effect in TRPV1-KO mice after ischemic brain injury 
To confirm that the protective effect of capsazepine was TRPV1-specific, we examined the effect 
of capsazepine in TRPV1-KO mice. rCBF was unaffected when vehicle or capsazepine was 
injected into TRPV1-KO mice at 30 min before MCA occlusion (Fig. 3A). Additionally, 
capsazepine had no significant effects on neurological deficiency, motor dysfunction, or infarct 
volume in TRPV1-KO (Figs. 3B, 3C, 3D, and 3E), indicating that the protective effects of 
capsazepine require TRPV1. 
 
The effect of TRPV1 deficiency on microglia/macrophages, astrocyte, and neutrophil 
accumulation 
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Finally, we examined accumulation of microglia/macrophages and astrocytes in the peri-ischemic 
area and of neutrophils in the ischemic core area at 1 and 2 days after ischemia by 
immunohistochemical staining for Iba1, GFAP, and Gr1, respectively. The numbers of 
Iba1-positive microglia/macrophages (Fig. 4A), GFAP-positive astrocytes (Fig. 4B), and 
Gr1-positive neutrophils (Fig. 4C) were higher at 1 and 2 days after cerebral ischemia; however, 
there were no differences between TRPV1-KO and WT mice with respect to the increases in the 





The present study clearly demonstrated that TRPV1 gene knockout attenuates neurological 
deficiency and motor dysfunction and reduces infarct volume after cerebral ischemia. Moreover, 
intracerebroventricular injection of capsazepine improved neurological outcome and reduced infarct 
volume in WT mice, but not in TRPV1-KO mice. These results suggest strongly that TRPV1 
activation has a deleterious effect on the pathophysiology of brain ischemia. 
  TRPV1 is expressed in a variety of cell types in both the peripheral and central nervous system [5, 
6], suggesting that it functions in several cell populations to increase the deleterious effects of 
ischemic brain injury. In this study, however, a single injection of capsazepine into the brain was as 
effective as global gene deletion of the TRPV1 gene in attenuating neurological deficit and motor 
dysfunction, and reduced infarct volume after ischemic brain injury, indicating that TRPV1 function 
at least affects recovery from ischemic brain injury. Previous reports indicate that TRPV1 is 
expressed in microglia [11, 12] and astrocytes [13] in the brain. In the present study, the number of 
Iba1-immunopositive microglia/macrophages, GFAP-immunopositive astrocytes 
Gr1-immunopositive neutrophils increased at 1 and 2 days after cerebral ischemia; however, no 
differences were observed between WT and TRPV1-KO mice, suggesting that TRPV1 in these cells 
is not critical for cerebral ischemic injury. 
  To date, electrophysiological studies clearly demonstrate that TRPV1 activation modifies synaptic 
transmission via both presynaptic [7, 8, 14-16] and postsynaptic mechanisms [9, 10]. Stimulation of 
TRPV1 by capsaicin or an endogenous TRPV1 agonist anadamide increased the frequency of 
spontaneous excitatory postsynaptic currents in dopaminergic neurons of the substantia nigra pars 
compacta [7], striatal neurons [14] and subpopulations of periaqueductal gray neurons [15]. 
Moreover, Shoudai et al. [16] reported that Ca2+ entry through TRPV1 channels triggered tonically 
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glutamate release independently of voltage-activated calcium channels in the central terminals of 
peripheral nerves. These studies clearly indicate that TRPV1 stimulation potentiates glutamatergic 
release in the CNS. Considering that glutamate is not only the primary excitatory neurotransmitter in 
the adult brain, but also a critical transmitter for the degeneration of signaling neurons following 
stroke [17], and that the levels of the TRPV1 endogenous agonists, palmitoylethanolamide [20] and 
anandamide [21], in the brain are elevated in cerebral ischemia, it is conceivable that atypical and 
excessive activation of TRPV1 during cerebral ischemia leads to the pathophysiological 
deterioration caused by neurotoxicity. Additionally, our previous data show endogenous stimulation 
of TRPV1-triggered neurotoxicity in cultured rat cortical neurons [18], indicating that 
TRPV1-mediated somatodendritic or postsynaptic Ca2+ influx could directly affect neuronal survival. 
If the expression level of TRPV1 is upregulated in the CNS neurons of stroke patients, as is 
previouly reported in mesial temporal lobe epilepsy patients [19], the neurotoxicity mediated by 
TRPV1would be further enhanced in cerebral ischemia.  
 Ischemic stroke increases anaerobic glycolysis and lactate accumulation, and decreases pH 
(acidosis) [22] in the brain. It also increases the accumulation of various neurotransmitters and 
inflammatory substances, including as major pain-causing substances bradykinin [23] and 
prostaglandin [24], which can induce the open state of the multistate TRPV1 receptor via 
phosphorylation by protein kinase C (PKC) induced by Gq/11-coupled receptor activation [4]. 
Additionally, a recent study revealed that bradykinin-induced PKC phosphorylation causes TRPV1 
activation and potentiates glutamatergic synaptic transmission at the first sensory synapse [25]. 
Taken together, TRPV1 in neurons could be activated under ischemic conditions in response to 
various stimuli, and this could lead to an increase in neurotoxic glutamate release and adverse effects 
on neuronal survival. 
  Although intracerebroventricular injection of the TRPV1 blocker capsazepine attenuated ischemic 
brain injury, nonspecific effects of capsazepine might be anticipated, such as inhibition of TRPM8 
[26]. In this study, however, the protective effect of capsazepine was not evident in TRPV1-KO mice, 
indicating that the attenuation of the deleterious effects of ischemic brain injury by capsazepine was 
TRPV1 specific.  
By contrast, previous research shows that TRPV1 activation exerts protective effects in a rodent 
ischemia model, possibly by inducing hypothermia [27, 28]. Although an injection of 25 mg/kg 
rinvanil, a TRPV1 agonist, induced hypothermia and exerted neuroprotective effects against cerebral 
ischemic injury, a higher dose (50 mg/kg) did not show any significant effect [27], indicating that 
excessive stimulation of TRPV1 can adversely affect neuronal survival. Furthermore, we evaluated 
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infarct volume under more severe conditions than those employed in a previous report using 
dihydrocapsaicin [28]. Therefore, it is possible that a difference in the extent of severity of brain 
injury explains the difference between our results and those reported previously, although further 
investigation will be needed to confirm this. In this context, further evidence that peripheral TRPV1 
activation is primarily involved in hypothermia comes from studies showing the involvement of 
constitutive activation of TRPV1 channels by protons in the abdominal viscera in thermoregulation 
[29] and attenuation of hyperthermia induced by a TRPV1 antagonist, AMG9810, by the 
β-adrenoceptor antagonist propranolol [30]. This notion is further reinforced by results showing that 
the TRPV1 antagonist AS1928370 with high brain penetrability has little effect on hyperthermia 
[31]. Thus, at low doses of the TRPV1 agonists that do affect neurons in the CNS, 
hypothermia-dependent ischemic neuroprotection might be the predominant effect. However, 
judging from the contradictory effects of TRPV1 on ischemia, therapeutic interventions designed to 
induce hypothermia via TRPV1 activation could entail a risk of CNS neurotoxicity triggered by 
mistakenly or unexpectedly high dose treatments with TRPV1 agonists. Taken together, selective 
inhibition of TRPV1 in the CNS with doses of antagonists that do not affect peripheral TRPV1 
activity could be more effective in preventing TRPV1-mediated neurotoxicity when used in 
combination with the well-established cooling system. 
  In conclusion, we suggest that TRPV1 plays a significant role in ischemic brain injury. TRPV1 
could be the promising target for clinical interventions designed to treat ischemic brain injury. 
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Fig. 1. Attenuation of the neurological and motor deficit and infarct volume in TRPV1-deficient 
mice. (A) Decreases in rCBF in the MCA territory were estimated by Laser-Doppler Flowmetry. 
Percent changes from baseline were recorded at baseline, at 5 min after induction of ischemia, 
and at 10 min intervals from onset of ischemia to 25 min after reperfusion, in WT and 
TRPV1-KO mice. (B) At 1 and 2 days after reperfusion, the neurological deficits of WT and 
TRPV1-KO mice (n = 15-22) were assessed. (C) At 1 and 2 days after reperfusion, the motor 
deficits of WT and TRPV1-KO mice (n = 15-22) were assessed. (D) Representative images of 
TTC stained coronal sections obtained from WT and TRPV1-KO mice. (D) Infarct volume at 2 
days after reperfusion in WT and TRPV1-KO mice (n = 8-9). *p < 0.05 vs. WT.  
  
 
Fig. 2. Protective effects of capsazepine pre-treatment on ischemic brain injury. (A) Decreases 
in rCBF in the MCA territory were estimated by Laser-Doppler Flowmetry. Percent changes 
from baseline were recorded at baseline, at 5 min after induction of ischemia, and at 10 min 
intervals from onset of ischemia to 25 min after reperfusion, in vehicle- and capsazepine- (20 
nmol) treated mice. (B) At 1 and 2 days after reperfusion, the neurological deficits of vehicle- 
and capsazepine-treated mice (n = 11, respectively) were assessed. (C) At 1 and 2 days after 
reperfusion, the motor deficits of vehicle- and capsazepine-treated mice (n = 11, respectively) 
were assessed. (D) Representative images of TTC-stained coronal sections obtained from 
vehicle- and capsazepine-treated mice. (E) Infarct volume at 2 days after reperfusion in vehicle- 
and capsazepine-treated mice (n = 11, respectively). *p < 0.05, **p < 0.01 vs. vehicle.  
 
Fig. 3. Null effect of capsazepine on infarct volume in TRPV1-deficient mice. (A) Decreases in 
rCBF in the MCA territory were estimated by Laser-Doppler Flowmetry. Percent changes from 
baseline were recorded at baseline, at 5 min after induction of ischemia, and at 10 min intervals 
from onset of ischemia to 25 min after reperfusion, in vehicle- and capsazepine- (20 nmol) 
treated TRPV1-KO mice. (B) At 1 and 2 days after reperfusion, the neurological deficits of 
vehicle- and capsazepine-treated TRPV1-KO mice (n = 10, respectively) were assessed. (C) At 
1 and 2 days after reperfusion, the motor deficits of vehicle- and capsazepine-treated 
TRPV1-KO mice (n = 10, respectively) were assessed. (D) Representative images of TTC 
stained coronal sections obtained from vehicle- and capsazepine-treated TRPV1-KO mice. (E) 
Infarct volume at 2 days after reperfusion in vehicle- and capsazepine-treated TRPV1-KO mice 
(n = 10, respectively). 
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Fig. 4. Null effect of TRPV1 deficiency on the number of microglia/macrophages, astrocytes 
and neutrophils after ischemia. The upper inset depicts ischemic core area (core), peri-infarct 
area (peri), and contralateral area (contra) in an ischemic brain slice. (A) Summarized data of 
the number of Iba1-positive cells at 1 and 2 days after ischemia (left) and representative images 
of Iba1-positive cells at 2 days after ischemia (right). (B) Summarized data of the number of 
GFAP-positive cells at 1 and 2 days after ischemia (left) and representative images of 
GFAP-positive cells at 2 days after ischemia (right). (C) Summarized data of the number of 
Gr1-positive cells at 1 and 2 days after ischemia (left) and representative images of Gr1-positive 
cells at 2 days after ischemia (right). n = 5–6, respectively. 
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